SCHEMBL3286208

SCHEMBL3286208

C[S+]([O-])c1ccc(Nc2nc(Nc3ccc4cn[nH]c4c3)c3cc[nH]c3n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.45
EGFR P00533 2/20 0.44
PDGFRB P09619 7/20 0.42
PDGFRA P16234 7/20 0.42
FGFR1 P11362 1/20 0.42
SYK P43405 4/20 0.41
RET P07949 2/20 0.40
CCNK O75909 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
KDR P35968 1/20 0.40
ROCK1 Q13464 2/20 0.40
ROCK2 O75116 1/20 0.40
HTR2C P28335 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278287 0.88 CDC7 (0.52) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL12082758 0.84 CDC7 (0.44) CDC7EGFRFGFR1SYKRET
SCHEMBL3286011 0.84 PLK4 (0.50) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL3280878 0.84 CDC7 (0.47) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL12085401 0.83 CCNK (0.46) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL3283879 0.82 KDR (0.50) CDC7EGFRFGFR1SYKKDR
SCHEMBL13387040 0.82 CDK1 (0.54) CDC7SYKRETCCNKCDK12
SCHEMBL12085316 0.80 PAK4 (0.46) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL12085487 0.80 CDC7 (0.46) CDC7EGFRPDGFRBPDGFRAFGFR1
SCHEMBL3286833 0.80 LRRK2 (0.57) CDC7EGFRPDGFRBPDGFRASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US claimed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 WO claimed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US claimed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK CDC7 610/4885EGFR 639/4885PDGFRB 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.